PRO-6E

Cat. No.:	HY-160506
CAS No.:	2353493-69-1
Molecular Formula:	$C_{42}H_{44}Cl_2FN_7O_7$
Molecular Weight:	848.75
Target:	c-Met/HGFR; Apoptosis; PROTACs
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis; PROTAC
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (117.82 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.1782 mL	5.8910 mL	11.7820 mL
5 mM	0.2356 mL	1.1782 mL	2.3564 mL
10 mM	0.1178 mL	0.5891 mL	1.1782 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

PRO-6E is an oral active PROTAC based on Cereblon ligand, and induces the degradation of MET with maximum degradation of 81.9% at 1 μM in MKN-45 cells. PRO-6E inhibits tumor growth in vivo and in vitro. PRO-6E induces cell apoptosis and induces cell arrest (Sturcture Note:(Blue: Cereblon ligand (HY-103596), Black: linker，Pink: ALK/c-Met inhibitor Crizotinib (HY-50878))[1].

In Vitro

PRO-6E (0.03-10 μM; 48 h) inhibits the cell growth in MKN-45, SNU-638 cells[1].

PRO-6 E (1 μM; over 24 h) facilitates MET degradation in MKN-45 cells[1].

PRO-6 E (0.1-1 μM; 48 h) increase in the percentage of G2/M phase cells and decrease in the percentage of S phase cells in MKN-45 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line:	MKN-45, SNU-638 cells

Concentration:	0, 0.03, 0.1, 0.3, 1, 3, 10 μM
Incubation Time:	48 h
Result:	Inhibited the cell growth.

Cell Cycle Analysis[1]

Cell Line:	MKN-45 cells
Concentration:	0, 0.1, 0.3, 1, 3 μM
Incubation Time:	48 h
Result:	Increased in the percentage of G2/M phase cells and decreased in the percentage of S phase cells.

Western Blot Analysis[1]

Cell Line:	MKN-45 cells
Concentration:	0, 0.03, 0.1, 0.3, 1, 3 μM
Incubation Time:	12, 24, 36, 48, and 72 h
Result:	facilitated MET degradation over 24 hours.

In Vivo

PRO-6E (oral gavage; 30 mg/kg/day for 15 days) inhibits tumor growth in MKN□45 cell□derived xenograft tumor model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MKN□45 cell□derived xenograft tumor model[1]
Dosage:	30 mg/kg/day for 15 days
Administration:	Oral gavage
Result:	Inhibited tumor growth.

REFERENCES

[1]. Chen JJ, et al. Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation. Cancer Sci. 2023;114(5):1958-1971.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA